Galapagos Pushes Bone and Joint Compounds Toward Phase I Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
New agents could beat standard of care in bone cancer metastases and rheumatoid arthritis, firm says.
You may also be interested in...
Pharma-Size That: Galapagos Expands RA Drug Development With Blockbuster J&J Deal
Alliance valued at over €1 billion includes potential landmark €60 million license on Galapagos' lead internal rheumatoid arthritis candidate GT418.
Galapagos Seeks Partner For Recently Acquired Low-Dose Estrogen Product
The firm continues its acquisition program with the purchase of ProStrakan’s bone disease unit for a maximum value of $60 million.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.